The Food and Drug Administration recently approved a new drug for Alzheimer's disease called donanemab, to be sold under the brand name Kisunla. This drug has shown to modestly slow cognitive decline in early stages of the disease, but also comes with significant safety risks such as swelling and bleeding in the brain. Kisunla, similar to the previously approved drug Leqembi, is an intravenous infusion that targets a protein involved in Alzheimer's. Both drugs can delay dementia progression by several months and have similar safety risks. However, Kisunla may be more appealing to patients, doctors, and insurers as Lilly claims that patients can stop the drug once the protein amyloid is cleared from the brain. This novel class of treatments for Alzheimer's has sparked a mix of hope, disappointment, and skepticism in the medical community.